ArcticZymes Technologies - Capital/Financing Update 2016

ArcticZymes awarded funding from the Horizon2020 programme

(Tromsø 01. April 2016) Biotec Pharmacon ASA ("Biotec",OSE: BIOTEC) is pleased

to announce that ArcticZymes, a subsidiary of Biotec Pharmacon has received EUR

460.000 over the next four years in a project funded by the European Framework

Programme for Research and Innovation, Horizon 2020.

"We are excited to participate in the new granted "Virus-X" EU Consortium. It

will allow ArcticZymes to expand its access to novel molecular enzymes via the

bioprospecting of a wide diversity of viral genomes.", says Jethro Holter,

Managing Director, ArcticZymes AS.

The project "Viral Metagenomics for Innovation Value" (Virus-X), is a large

collaboration project between a total of 15 partners from European research

institutes, universities and industry with a total budget of nearly 8 M Euro , funded

under Horizon2020 - Research and Innovation Action (RIA). Viruses represent the

largest reservoir of unknown genetic diversity on earth and the project aim to

advance the understanding of viral ecosystems, diversity and virus-host

interplay by DNA sequencing environmental libraries (metagenomes) from a number

of different biotopes. The project is driven by the expected large innovation

value and unique properties of viral gene products. Through an analysis and

discovery pipeline, new enzymes for molecular biotechnology will be developed,

and ArcticZymes is one of the industrial partners that will participate

developing and bringing new viral enzymes to the market.

"This is a milestone and great achievement of ArcticZymes. This acknowledges

ArcticZymes experience and knowledge as a leading enzyme company within in the

EU system", say Svein Lien, CEO, Biotec Pharmacon ASA.

For additional information:

Børge Sørvoll, CFO

+47 952 90187

Jetro Holter, MD ArcticZymes

+47 468 59146

About Biotec Pharmacon:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics.

AI assistant